Skip to main content Skip to section navigation Skip to footer
  • About
    • Discover Mineralys
    • Purpose & Values
    • Our Team
  • Science
    • Lorundrostat
    • Aldosterone
    • Hypertension
    • Cardio-Renal-Metabolic Syndrome
  • Pipeline
  • Investors
  • Publications
  • Contact Us
    • Careers & Culture
    • Partnering
    • Contact Form
Menu
  • About
    • Discover Mineralys
    • Purpose & Values
    • Our Team
  • Science
    • Lorundrostat
    • Aldosterone
    • Hypertension
    • Cardio-Renal-Metabolic Syndrome
  • Pipeline
  • Investors
  • Publications
  • Contact Us
    • Careers & Culture
    • Partnering
    • Contact Form

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • SEC Filings
    • All SEC Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
May 12, 2025 4:05 pm EDT

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 07, 2025 8:00 am EDT

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

May 05, 2025 4:05 pm EDT

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

Apr 23, 2025 5:23 pm EDT

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

Mar 29, 2025 2:30 pm EDT

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

Mar 25, 2025 8:00 am EDT

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mar 18, 2025 4:01 pm EDT

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mar 17, 2025 8:00 am EDT

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo

Mar 11, 2025 10:20 pm EDT

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Mar 10, 2025 4:01 pm EDT

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2025 Mineralys Therapeutics, LLC
  • Terms & Conditions
  • Privacy Policy
  • X/Twitter Icon Twitter
  • Linkedin